



WD1646 Box seq
PATENT
454311-2200.1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Hanes et al.
U.S. Serial No. : 09/507,242
Filing Date : February 18, 2000
For : *CaESS1*: A CANDIDA ALBICANS GENE,
METHODS FOR MAKING AND USING, AND
TARGETING IT OR ITS EXPRESSION PRODUCTS
FOR ANTIFUNGAL APPLICATIONS

RECEIVED

JUN 07 2000

TECH CENTER 1600/2900

745 Fifth Avenue
New York, NY 10151

I hereby certify that this correspondence is being deposited with
the United States Postal Service as first class mail in an envelope
addressed to: Assistant Commissioner for Patents, Washington,
DC 20231, on

2 June 2000
Thomas J. Kowalski, Reg. No. 32,147

Name of Applicant, Assignee or Registered Representative

Thomas J. Kowalski
Signature

2 June 2000
Date of Signature

RECEIVED

JUN 09 2000

TECH CENTER 1600/2900

**AMENDMENT TO COMPLY WITH REQUIREMENTS FOR
PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Box Sequence
Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Please accept the enclosed sequence listing, a machine readable disk including
same, the required Statements under 37 C.F.R. §1.821 (f) and (g) (below) and please amend the
above-captioned application as follows:

IN THE SPECIFICATION:

Please amend the specification as follows:

Immediately after page 41 and before the first page of claims (page 42), if
appropriate, please insert the enclosed pages identified as --Sequence Listing--.

REMARKS

It is believed that the Sequence Listing conforms to the requirements of the 37 C.F.R. §1.823 (b). The Statements required by 37 C.F.R. §1.821 (f) and (g) are set forth below.


Pursuant to 37 C.F.R. §1.821 (g), the undersigned attorney of record hereby states that this submission, filed in accordance with 37 C.F.R. §1.821 (g), does not contain new matter.

Pursuant to 37 C.F.R. §1.821 (f), the undersigned attorney hereby states that the content of the paper and computer readable copies of the Sequence Listing submitted in accordance with 37 C.F.R. §1.821 (c) and (e), respectively, are the same. No new matter is added by the specification amendments herewith.

In view of the amendments, remarks and enclosures herewith, the application complies with the requirements for computer readable disclosure of the biological sequences under 37 C.F.R. §1.821-1.825. Please charge any additional fees incurred by reason of this Response to Deposit Account No. 50-0320.

Respectfully submitted,
FROMMER LAWRENCE & HAUG LLP

By:


Thomas J. Kowalski
Reg. No. 32,147
(212) 588-0800

Enclosures: Paper and Disk Sequence Listing